Page 55«..1020..54555657..6070..»

Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with…

By Dr. Matthew Watson

Daix (France), Long Island City (New York, United States), July 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical needs, today announced the screening in the United States of America of the first patient in its LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D 1. Over 30 sites located in France, United Kingdom, Belgium, Netherlands and United States have already been qualified to participate in this clinical trial. Topline results are expected to be published in the second half of 2023.

Here is the original post:
Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with...

To Read More: Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with…
categoriaGlobal News Feed commentoComments Off on Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with… | dataJuly 8th, 2022
Read All

Societal CDMO Reports Inducement Grants for New Staff

By Dr. Matthew Watson

SAN DIEGO and GAINESVILLE, Ga., July 07, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the addition of new employees to fill open roles throughout the organization.

Read the original:
Societal CDMO Reports Inducement Grants for New Staff

To Read More: Societal CDMO Reports Inducement Grants for New Staff
categoriaGlobal News Feed commentoComments Off on Societal CDMO Reports Inducement Grants for New Staff | dataJuly 8th, 2022
Read All

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

By Dr. Matthew Watson

OXFORD, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 in New York, July 11 to 12. Mr. Enright will also host one on one meetings with investors at the conference.

View original post here:
Vaccitech to Present at the William Blair Biotech Focus Conference 2022

To Read More: Vaccitech to Present at the William Blair Biotech Focus Conference 2022
categoriaGlobal News Feed commentoComments Off on Vaccitech to Present at the William Blair Biotech Focus Conference 2022 | dataJuly 8th, 2022
Read All

Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update

By Dr. Matthew Watson

NX-2127 advanced to Phase 1b in CLL based on promising data in Phase 1a clinical trial

The rest is here:
Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update

To Read More: Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update
categoriaGlobal News Feed commentoComments Off on Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update | dataJuly 8th, 2022
Read All

Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant…

By Dr. Matthew Watson

BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/.

Visit link:
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant...

To Read More: Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant…
categoriaGlobal News Feed commentoComments Off on Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant… | dataJuly 8th, 2022
Read All

Nicox: 2022 Extraordinary Shareholder Meeting

By Dr. Matthew Watson

Read the original here:
Nicox: 2022 Extraordinary Shareholder Meeting

To Read More: Nicox: 2022 Extraordinary Shareholder Meeting
categoriaGlobal News Feed commentoComments Off on Nicox: 2022 Extraordinary Shareholder Meeting | dataJuly 8th, 2022
Read All

Bionomics to Participate in William Blair’s Biotech Focus Conference 2022

By Dr. Matthew Watson

ADELAIDE, Australia, July 08, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Dr. Errol De Souza, Executive Chairman of Bionomics, will participate in a panel on “Unmet Needs and Novel Therapies in Neuropsychiatry” at the William Blair Biotech Focus Conference taking place virtually and in-person in New York on July 12-13, 2022.

More:
Bionomics to Participate in William Blair’s Biotech Focus Conference 2022

To Read More: Bionomics to Participate in William Blair’s Biotech Focus Conference 2022
categoriaGlobal News Feed commentoComments Off on Bionomics to Participate in William Blair’s Biotech Focus Conference 2022 | dataJuly 8th, 2022
Read All

Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program

By Dr. Matthew Watson

Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis

Read the original here:
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program

To Read More: Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
categoriaGlobal News Feed commentoComments Off on Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program | dataJuly 8th, 2022
Read All

ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”

By Dr. Matthew Watson

TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 08, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has received final approval from The Nasdaq Capital Market LLC (“Nasdaq”) to list its common shares (the “Common Shares”) on Nasdaq. The Company’s Common Shares will begin trading on Friday, July 8th, 2022, under the symbol “PMN”.

Excerpt from:
ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”

To Read More: ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”
categoriaGlobal News Feed commentoComments Off on ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN” | dataJuly 8th, 2022
Read All

SIGA Technologies Receives Approval from UK for Tecovirimat

By Dr. Matthew Watson

Treatment Approved for Smallpox, Monkeypox, Cowpox, and Vaccinia Complications Treatment Approved for Smallpox, Monkeypox, Cowpox, and Vaccinia Complications

Original post:
SIGA Technologies Receives Approval from UK for Tecovirimat

To Read More: SIGA Technologies Receives Approval from UK for Tecovirimat
categoriaGlobal News Feed commentoComments Off on SIGA Technologies Receives Approval from UK for Tecovirimat | dataJuly 8th, 2022
Read All

Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan

By Dr. Matthew Watson

WATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Leigh Morgan to its Board of Directors. Ms. Morgan joins Kymera’s Board as a senior executive accomplished in scaling global, profitable, high-performing organizations.

See the article here:
Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan

To Read More: Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan
categoriaGlobal News Feed commentoComments Off on Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan | dataJuly 8th, 2022
Read All

Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy

By Dr. Matthew Watson

ILUVIEN receives approval and pricing for non-infectious uveitis affecting the posterior segment indication in July; launch to follow ILUVIEN receives approval and pricing for non-infectious uveitis affecting the posterior segment indication in July; launch to follow

Read the original post:
Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy

To Read More: Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy
categoriaGlobal News Feed commentoComments Off on Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy | dataJuly 8th, 2022
Read All

OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update

By Dr. Matthew Watson

ROCKVILLE, Md., July 08, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that total preliminary unaudited revenue for the second quarter of 2022 was approximately $1.0 million, up from $0.8 million in the second quarter of 2021. Cash as of June 30, 2022 was approximately $16.6 million.

Go here to see the original:
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update

To Read More: OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update
categoriaGlobal News Feed commentoComments Off on OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update | dataJuly 8th, 2022
Read All

MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13

By Dr. Matthew Watson

YAVNE, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced an oral presentation at the Advanced Wound Care Summit taking place on July 13-14, 2022 in Boston, MA.

Follow this link:
MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13

To Read More: MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13
categoriaGlobal News Feed commentoComments Off on MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13 | dataJuly 8th, 2022
Read All

Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

By Dr. Matthew Watson

- Adverum to present new best-corrected visual acuity (BCVA) data from the OPTIC Trial of ADVM-022 (ixoberogene soroparvovec) in wet AMD

See original here:
Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

To Read More: Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022
categoriaGlobal News Feed commentoComments Off on Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022 | dataJuly 8th, 2022
Read All

Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel

By Dr. Matthew Watson

PRINCETON, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be participating in a virtual panel discussion presented by Maxim Group LLC and hosted by M-Vest. Full details on the panel are as follows:

See the rest here:
Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel

To Read More: Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel
categoriaGlobal News Feed commentoComments Off on Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel | dataJuly 8th, 2022
Read All

Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13

By Dr. Matthew Watson

BRIDGEWATER, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will attend the 12th Annual World Orphan Drug Congress USA 2022, being held at the Hynes Convention Center in Boston, on July 11-13, 2022.

Visit link:
Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13

To Read More: Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13
categoriaGlobal News Feed commentoComments Off on Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13 | dataJuly 8th, 2022
Read All

SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment…

By Dr. Matthew Watson

TEL AVIV, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has started the process of preparing for an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for its Phase IIb clinical trial for SCI-110 in patients suffering from Tourette Syndrome ("TS").

Read this article:
SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment...

To Read More: SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment…
categoriaGlobal News Feed commentoComments Off on SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment… | dataJuly 8th, 2022
Read All

Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent…

By Dr. Matthew Watson

Key patent strengthens proprietary position in China until August 2031 Key patent strengthens proprietary position in China until August 2031

Read more here:
Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent...

To Read More: Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent…
categoriaGlobal News Feed commentoComments Off on Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent… | dataJuly 8th, 2022
Read All

Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022

By Dr. Matthew Watson

BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to view on-demand beginning Monday, July 11, 2022. Management will be available for in-person meetings at the conference on Tuesday, July 12, 2022.

See the original post here:
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022

To Read More: Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022
categoriaGlobal News Feed commentoComments Off on Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022 | dataJuly 8th, 2022
Read All

Page 55«..1020..54555657..6070..»


Copyright :: 2024